Economy/Home · Economy

Qurcell Receives MFDS Approval for Change in Phase 1/2 Clinical Trial Plan for Leukemia Drug 'Anbalcel'… ALL Trial to Be Run Independently and Efficiently

Qurcell announced in a regulatory filing on the 18th that it has received approval from the Ministry of Food and Drug Safety (MFDS) for a change to its Phase 1/2 investigational new drug (IND) application for 'Anbalcel' (CRC01, anbalcaptagene autoleucel), a candidate treatment for adult B-cell acute

Oseong Kwon
Staff Reporter
5 min read
Qurcell Receives MFDS Approval for Change in Phase 1/2 Clinical Trial Plan for Leukemia Drug 'Anbalcel'… ALL Trial to Be Run Independently and Efficiently
CBC News

Qurcell announced in a regulatory filing on the 18th that it has received approval from the Ministry of Food and Drug Safety (MFDS) for a change to its Phase 1/2 investigational new drug (IND) application for 'Anbalcel' (CRC01, anbalcaptagene autoleucel), a candidate treatment for adult B-cell acute lymphoblastic leukemia.

[Background of the Change Approval] This change approval involves separating the clinical trial protocol in order to operate the acute lymphoblastic leukemia (ALL) clinical trial independently and efficiently, following the product approval for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Qurcell applied for the change approval on October 27 and received notification of approval on November 18.

[Clinical Trial Overview] This is a domestic Phase 1/2 clinical trial evaluating the tolerability, safety, and efficacy of CRC01 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia (B-ALL). It is being conducted as an open-label, multicenter, single-arm trial at Seoul St. Mary's Hospital and other sites.

[Phase 1 and Phase 2 Design] In Phase 1, the tolerability of CRC01 will be evaluated and the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) will be determined. In Phase 2, efficacy will be evaluated with the overall complete remission rate (OCR), based on independent assessment, as the primary endpoint. The overall complete remission rate is the sum of complete remission (CR) and complete remission with incomplete hematologic recovery (CRi).

The primary analysis of Phase 2 will be conducted when patients complete the 3-month visit after CRC01 administration or drop out before then. The trial is designed so that efficacy is considered demonstrated if the lower limit of the one-sided 97.5% normal approximation confidence interval for the overall complete remission rate exceeds 40%.

[Subject Size and Schedule] The target number of subjects is up to 18 in Phase 1 and approximately 43 who complete CRC01 dosing in Phase 2. The clinical trial period is approximately 86 months from the date of MFDS and Institutional Review Board (IRB) approval, and may change depending on subject enrollment. The disclosed expected completion date is September 30, 2028.

[Investment Cautions] Qurcell explained that investigational drugs are statistically known to have an approximately 10% probability of ultimately receiving drug approval. It also stated that if results fall short of expectations during the clinical trial or product approval process, it may change or abandon its commercialization plans.

Oseong Kwon
Staff Reporter

CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.